Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Fintech Innovation ETF (ARKF) vs Cassava Sciences Inc (FLNA) Price & Performance

ARK Fintech Innovation ETF
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

ARK Fintech Innovation ETF vs Cassava Sciences Inc — how do they compare? ARK Fintech Innovation ETF trades at $41.45, while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: ARK Fintech Innovation ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ARKFFLNA
Sector
Sector/ThematicHealth
52-Week High
$58.82$4.64
52-Week Low
$36.14$1.16
Market Cap
$57.49M
Enterprise Value
-$29.09M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Fintech Innovation ETF

ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.

The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

About ARK Fintech Innovation ETF

ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.

Read more on ARKF

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA